{"id":23653,"date":"2022-05-03T11:26:24","date_gmt":"2022-05-03T10:26:24","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=23653"},"modified":"2022-05-03T11:26:28","modified_gmt":"2022-05-03T10:26:28","slug":"antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/","title":{"rendered":"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable"},"content":{"rendered":"\n<p>Article publi\u00e9 sur <a href=\"https:\/\/news.dayfr.com\/health\/amp\/542582\" target=\"_blank\" rel=\"noreferrer noopener\">News Day FR<\/a> le 02 mai 2022<\/p>\n\n\n\n<p>L&#8217;<strong>Agence espagnole des m\u00e9dicaments et des produits de sant\u00e9<\/strong>\u00a0(Aemps), d\u00e9pendant du Minist\u00e8re de la Sant\u00e9, a \u00e9mis une alerte de retrait pour un antibiotique couramment utilis\u00e9 apr\u00e8s avoir obtenu des \u201cr\u00e9sultats hors sp\u00e9cifications\u201d dans le cadre de \u201cl\u2019\u00e9tude de stabilit\u00e9 dans les tests d\u2019apparence, d\u2019humidit\u00e9 et d\u2019impuret\u00e9s\u201d. Les m\u00e9dicaments concern\u00e9s sont\u00a0<strong>Zinnat<\/strong>, qui \u00e9limine les infections bact\u00e9riennes chez les enfants et les adultes.<\/p>\n\n\n\n<p>Plus pr\u00e9cis\u00e9ment, il s\u2019agit de&nbsp;<strong>Zinnat 250 mg \u2018Granul\u00e9s pour suspension buvable\u2019<\/strong>, dans un format de 10 enveloppes (NR : 59063, CN : 695631). Le num\u00e9ro de lot est FS4S, avec date d\u2019expiration&nbsp;<strong>31\/10\/2022<\/strong>.<\/p>\n\n\n\n<p>L\u2019AEMPS&nbsp;<strong>a demand\u00e9 le retrait du march\u00e9 de toutes les parts<\/strong>&nbsp;distribu\u00e9s \u00e0 partir des lots concern\u00e9s et renvoy\u00e9s au laboratoire par les voies habituelles ; et aux Communaut\u00e9s autonomes qui surveillent le retrait.<\/p>\n\n\n\n<p>Acuprel, dont le principe actif est\u00a0<strong>C\u00e9furoxime ax\u00e9til<\/strong> est un antibiotique utilis\u00e9 pour traiter\u00a0<strong>infections de la gorge<\/strong>, des sinus du nez, de l\u2019oreille moyenne, des poumons ou du thorax, des voies urinaires de la peau et des tissus mous. \u201cZinnat peut \u00e9galement \u00eatre utilis\u00e9 pour traiter\u00a0<strong>maladie de Lyme<\/strong>\u00a0(infection transmise par les tiques) \u00bb, explique la notice.<\/p>\n\n\n\n<p>Pour les adultes, la dose recommand\u00e9e de Zinnat est&nbsp;<strong>250 mg \u00e0 500 mg deux fois par jour<\/strong>, selon la gravit\u00e9 et le type d\u2019infection. Pour les enfants, la dose recommand\u00e9e de Zinnat est de 10 mg\/kg de poids de l\u2019enfant (jusqu\u2019\u00e0&nbsp;<strong>un maximum de 125 mg<\/strong>) \u00e0 15 mg\/kg de poids de l\u2019enfant (<strong>jusqu\u2019\u00e0 un maximum de 250 mg<\/strong>) deux fois par jour. La posologie finale d\u00e9pendra de la gravit\u00e9 et du type d\u2019infection, du poids et de l\u2019\u00e2ge de l\u2019enfant, jusqu\u2019\u00e0 un maximum de 500 mg par jour.&#8212;<\/p>\n\n\n\n<p>L\u2019Aemps classe les d\u00e9fauts de qualit\u00e9 des m\u00e9dicaments en trois cat\u00e9gories (1, 2 et 3). La premi\u00e8re d\u2019entre elles correspond \u00e0 un risque plus \u00e9lev\u00e9, et la classe trois \u00e0 un risque plus faible. Dans ce cas, l\u2019Aemps rappelle qu\u2019il est\u00a0<strong>un d\u00e9faut de classe deux<\/strong>.<\/p>\n\n\n\n<p>Les antibiotiques sont utilis\u00e9s pour traiter les infections bact\u00e9riennes et\u00a0<strong>ils ne sont pas utilis\u00e9s pour traiter les infections virales telles que la grippe ou le rhume\u201d<\/strong>, souvenez-vous des Aemps. \u201cIl est important que vous suiviez les instructions concernant la dose, les apports et la dur\u00e9e du traitement indiqu\u00e9s par votre m\u00e9decin.\u00a0<\/p>\n\n\n\n<p><strong>Ne conservez pas et ne r\u00e9utilisez pas ce m\u00e9dicament<\/strong>. <\/p>\n\n\n\n<p>S\u2019il vous reste des antibiotiques apr\u00e8s la fin du traitement, rapportez-les \u00e0 la pharmacie pour une \u00e9limination appropri\u00e9e. Les m\u00e9dicaments ne doivent pas \u00eatre jet\u00e9s dans les \u00e9gouts ou \u00e0 la poubelle.\u201d<\/p>\n\n\n\n<p>L\u2019utilisation inappropri\u00e9e d\u2019antibiotiques est l\u2019une des principales causes de la soi-disant \u2018<strong>r\u00e9sistance bact\u00e9rienne<\/strong>\u2018, le fait que les souches deviennent r\u00e9sistantes aux traitements et aggravent les infections. La plus grande analyse \u00e0 ce jour, publi\u00e9e en janvier dans&nbsp;<em>Le Lancet<\/em>, rappelle que les bact\u00e9ries \u201csuper-r\u00e9sistantes\u201d ont caus\u00e9 1,27 million de d\u00e9c\u00e8s en 2019. \u201c<strong>Plus, m\u00eame, que le sida ou le paludisme<\/strong>avec jusqu\u2019\u00e0 860 000 et 640 000 d\u00e9c\u00e8s cette ann\u00e9e-l\u00e0, respectivement.\u201d<\/p>\n\n\n\n<p>Bruno Gonz\u00e1lez-Zorn, professeur au D\u00e9partement de sant\u00e9 animale de la Facult\u00e9 de m\u00e9decine v\u00e9t\u00e9rinaire de l\u2019Universit\u00e9 Complutense de Madrid et conseiller aupr\u00e8s de l\u2019OMS, parle d\u2019\u201dune pand\u00e9mie silencieuse\u201d. Comme il l\u2019explique, \u00ab\u00a0l\u2019utilisation inappropri\u00e9e est le principal moteur de la r\u00e9sistance et pour cette raison, ils doivent \u00eatre r\u00e9duits \u00bb, soulignant que dans le monde au moins\u00a0<strong>un tiers des antibiotiques sont prescrits de mani\u00e8re inappropri\u00e9e<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article publi\u00e9 sur News Day FR le 02 mai 2022 L&#8217;Agence espagnole des m\u00e9dicaments et des produits de sant\u00e9\u00a0(Aemps), d\u00e9pendant du Minist\u00e8re de la Sant\u00e9, a \u00e9mis une alerte de retrait pour un antibiotique couramment utilis\u00e9 apr\u00e8s avoir obtenu des \u201cr\u00e9sultats hors sp\u00e9cifications\u201d dans le cadre de \u201cl\u2019\u00e9tude de stabilit\u00e9 dans les tests d\u2019apparence, d\u2019humidit\u00e9 [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":23663,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-03T10:26:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-03T10:26:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"455\" \/>\n\t<meta property=\"og:image:height\" content=\"348\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable\",\"datePublished\":\"2022-05-03T10:26:24+00:00\",\"dateModified\":\"2022-05-03T10:26:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\"},\"wordCount\":643,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\",\"name\":\"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg\",\"datePublished\":\"2022-05-03T10:26:24+00:00\",\"dateModified\":\"2022-05-03T10:26:28+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg\",\"width\":455,\"height\":348,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/","og_locale":"fr_FR","og_type":"article","og_title":"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-05-03T10:26:24+00:00","article_modified_time":"2022-05-03T10:26:28+00:00","og_image":[{"width":455,"height":348,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable","datePublished":"2022-05-03T10:26:24+00:00","dateModified":"2022-05-03T10:26:28+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/"},"wordCount":643,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/","name":"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg","datePublished":"2022-05-03T10:26:24+00:00","dateModified":"2022-05-03T10:26:28+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/05\/Panneau-danger.jpg","width":455,"height":348,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/antibiotique-retire-du-marche-zinnat-250-mg-granules-pour-suspension-buvable\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Antibiotique retir\u00e9 du march\u00e9 : Zinnat 250 mg, Granul\u00e9s pour suspension buvable"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-19 07:24:39","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/23653"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=23653"}],"version-history":[{"count":9,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/23653\/revisions"}],"predecessor-version":[{"id":23675,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/23653\/revisions\/23675"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/23663"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=23653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=23653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=23653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}